Analyst Research Report Snapshot

Title:

Kedem Pharmaceuticals Inc. (KDMP) - Financial Analysis Review

Price:

$125.00

Provider:

GlobalData

Date:

05 Nov 2012

Pages:

27

Type:

AcrobatPDF

Companies referenced:

KDMP.PK

Available for Immediate Download
Summary:

Kedem Pharmaceuticals Inc. (KDMP) - Financial Analysis Review Summary Kedem Pharmaceuticals Inc. (Kedem), formerly Global Health Ventures Inc., is a specialty pharmaceutical company. It develops the process of drug delivery and formulation. The company conducts the development of platform technologies for drug delivery through the sublingual (under the tongue) route. It designs new drugs by using “NNN” (new dosage form, new formulation, and for new uses) from existing FDA approved generic drugs. GlobalData's Kedem Pharmaceuticals Inc. (KDMP) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Kedem Pharmaceuticals Inc. Key Recent Developments: Jun 27, 2012: Kedem Pharma Promotes Lola Maksumova To COO Apr 16, 2012: Kedem Pharma Reports Q3 Fiscal 2012 Results Jan 19, 2012: Kedem Pharma Reports Q2 Fiscal 2012 Results Dec 21, 2011: Kedem Pharma Begins Trading Under Symbol KDMP.ob Nov 08, 2011: Global Health Ventures Name Change And Corporate Restructuring This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.